MedStar Family Choice

MEDSTAR FAMILY CHOICE FORMULARY UPDATES

October 21, 2026 Pharmacy and Therapeutics Committee Meeting

MedStar Family Choice (MFC) Pharmacy and Therapeutics Committee meets quarterly. During the October 21, 2026 meeting, these formulary changes were made. Bolded names indicate a brand medication; other listed medications are generic.

SUMMARY OF FORMULARY CHANGES: EFFECTIVE OCTOBER 21, 2026	
Medication Name	**Change Applied**
Liraglutide (generic of **Victoza**)	Prior authorization removed
Mounjaro (tirzepatide injection)	New prior authorization criteria
Ozempic (semaglutide injection and tablets)	New prior authorization criteria
Rybelsus (semaglutide tablets)	New prior authorization criteria

FORMULARY UPDATE DETAILS | EFFECTIVE OCTOBER 21, 2026	
Medication Impacted	**Decision Details**
Liraglutide (generic of **Victoza**)	Prior authorization removed. No PA needed to start therapy for type 2 diabetes (age 10 and older).
Mounjaro (tirzepatide)	New PA criteria. Type 2 diabetes, age 10 and older. Requires A1c or CGM time in range (TIR) from the last 90 days and uACR from the last 12 months. Qualifies with A1c ≥7.5% or TIR ≤60%, or established ASCVD with A1c ≥6.5%. Step therapy: 3-month trial of two diabetes agents, then 3 months of liraglutide. Initial approval 6 months; renewal 12 months with improved or at-goal A1c/TIR and 90 days of adherence.
Ozempic (semaglutide injection and tablets), **Rybelsus**	New PA criteria. Same as Mounjaro, for adults 18 and older. Ozempic injection only may also qualify for diabetic kidney disease (eGFR 25 to <50 with uACR >100 mg/g, or eGFR 50–75 with uACR >300 mg/g) after a preferred SGLT2 inhibitor, with no liraglutide step.

Members with a current approval keep it until its end date; renewal criteria apply after that.

---

*Please see the Prior Authorization and Step Therapy Table for clinical criteria. The table is updated regularly. Please use the most current version found on the MFC Providers page: https://www.medstarfamilychoicemd.com/maryland-providers/pharmacy-prescription-information

The MFC P&T Committee welcomes your feedback. Providers can email feedback or requests for formulary changes to: MFC-FormularyFeedback@MedStar.net